FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT (	OF CHANGES IN	<b>BENEFICIAL</b>	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average but	urden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LOPEZ GEORGE A</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol ICU MEDICAL INC/DE [ ICUI ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) 951 CAL	(Fi	•	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/21/2022								Officer (give title Other (specify below) below)				specify
(Street) SAN CLEME  (City)			92673 (Zip)		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1) (Instr. 3			5. Amount of Securities Beneficially Owned Following Reported		Form: Direct Ind (D) or Indirect Bei (I) (Instr. 4) Ow		Nature of direct neficial vnership				
									Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 and				nstr. 4)
Common Stock 09/21/20				/2022	:022		M		79,576	A	\$61.76	361,020		D				
Common	Stock													886,843 I by Partnersh			y artnership	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion   Date   Execution Date,   r Exercise   (Month/Day/Year)   if any   (Month/Day/Year)   erivative			ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to buy)	\$61.76	09/21/2022			М			79,576	02/06/20	)17 <sup>(1)</sup>	02/06/2023	Common Stock	79,576	\$0.0	0		D	

## **Explanation of Responses:**

1. Options vest and are exercisable as to 25% of the underlying grant one year after the date of grant and in equal monthly installments thereafter for three additional years.

By: Paula Darbyshire, Attorney-in-fact For: George A. 09/21/2022 Lopez, M.D.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).